176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332)

Abstract

The phase II GeparOla study randomized patients (pts) with homologous recombination deficient (HRD), HER2-negative early breast cancer (BC) to receive neoadjuvant treatment with paclitaxel 80 mg/m2 iv weekly plus olaparib tablets 100 mg (PO) twice daily for 12 weeks or paclitaxel plus carboplatin AUC 2 iv (PCb) weekly for 12 weeks (PCb) prior to epirubicin/cyclophosphamide (EC). We determined pathological complete response (pCR, ypT0/is ypN0) according to treatment arm and germline mutation status.